MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4143/crt.2025.297

Медицинская библиотека · Cancer research and treatment · 2025

Prognostic Landscape of TP53 Mutations in Hematologic Malignancies.

Jang Seo Yoon, Jang Joowon, Lee Jee-Soo, Seong Moon-Woo, Park Songyi, Byun Ja Min, Koh Youngil, Hong Junshik, Kim Inho, Yoon Sung-Soo, Shin Dong-Yeop

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: While TP53 mutations are well known to be associated with adverse prognosis in hematological diseases, their functional impact remains incompletely understood. This study examines the spectrum of TP53 mutations across various hematologic malignancies and evaluates their functional impact.

MATERIALS AND

METHODS

Using targeted sequencing panels, we analyzed TP53 mutations in the bone marrow aspiration samples of a retrospective cohort of 856 patients diagnosed with hematologic malignancies. To assess the impact of TP53 mutations, we applied the evolutionary action (EAp53) score and the relative fitness score (RFS), previously proposed functional scoring methods. The effects of variant allele frequency (VAF), disruptive mutations, EAp53 score, and RFS on overall survival (OS) were evaluated.

RESULTS

TP53 mutations were associated with inferior OS compared with wildtype TP53 (median OS 10.0 months versus not estimable; hazard ratio (HR) 4.6; p<0.001). In the acute myeloid leukemia, multiple myeloma, and myelodysplastic syndrome subgroups, TP53 mutations had a significant adverse impact on OS. (HRs 3.8, 4.2, 6.0, respectively; p<0.001, p=0.005, p<0.001, respectively). Patients with VAF >50% had significantly poorer OS compared to those with VAF ≤50% (median OS 7.5 months versus 22.8 months; HR 2.2, p=0.016). Moreover, patients in the high-risk RFS group (RFS >0.22) had significantly worse OS compared to those in the low-risk RFS group (RFS ≤0.22) (median OS 5.6 months versus 16.3 months; HR 2.2, p=0.041). However, no significant survival difference was observed between the EAp53 high-risk (>75) and low-risk (≤75) groups, or between patients with disruptive and non-disruptive mutations.

CONCLUSION

Our findings highlight VAF and RFS as valuable tools for stratifying TP53-mutant patients into high-risk and low-risk groups.

Для цитирования: Jang Seo Yoon, Jang Joowon, Lee Jee-Soo, Seong Moon-Woo, Park Songyi, Byun Ja Min, Koh Youngil, Hong Junshik, Kim Inho, Yoon Sung-Soo, Shin Dong-Yeop. Prognostic Landscape of TP53 Mutations in Hematologic Malignancies.. Cancer research and treatment. 2025. DOI: 10.4143/crt.2025.297.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.